New cancer drugs that bind to KRAS G12C whether it is active or inactive turn off cancer signaling faster than older drugs, but after several hours, both types of drugs suppress the signal to the same extent.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether dual-state KRAS G12C inhibitors consistently improve progression-free survival or overall survival compared to inactive-state inhibitors across multiple randomized clinical trials in patients with KRAS G12C-mutant cancers.
A systematic review and meta-analysis of all completed and ongoing phase III randomized controlled trials comparing dual-state KRAS G12C inhibitors (e.g., compound 8) versus inactive-state inhibitors (e.g., sotorasib or adagrasib) in adults with advanced KRAS G12C-mutant non-small cell lung cancer or pancreatic cancer, with primary endpoints of overall survival and progression-free survival, stratified by prior therapy and tumor burden.
Whether dual-state KRAS G12C inhibitors improve clinical outcomes such as tumor shrinkage or survival compared to inactive-state inhibitors in patients with KRAS G12C-mutant cancers.
A multicenter, double-blind, randomized controlled trial of 500+ adults with advanced KRAS G12C-mutant NSCLC, randomized 1:1 to receive oral compound 8 (150 mg daily) or divarasib (120 mg daily) for 24 months, with primary endpoint of progression-free survival by RECIST 1.1, secondary endpoints including overall survival, objective response rate, and time to treatment failure.
Whether patients treated with dual-state KRAS G12C inhibitors have longer duration of response or lower rates of acquired resistance compared to those treated with inactive-state inhibitors in real-world clinical settings.
A prospective multicenter cohort study of 300+ patients with KRAS G12C-mutant NSCLC or colorectal cancer treated with either a dual-state inhibitor or an inactive-state inhibitor, tracking tumor response, resistance mechanisms via serial ctDNA, and survival over 3 years, adjusting for age, performance status, and prior therapies.
Whether resistance to dual-state KRAS G12C inhibitors is associated with specific genomic alterations (e.g., RTK amplifications or NRAS mutations) compared to resistance to inactive-state inhibitors.
A case-control study comparing tumor genomic profiles of 50 patients with acquired resistance to dual-state KRAS G12C inhibitors (cases) versus 50 patients with acquired resistance to inactive-state inhibitors (controls), using whole-exome sequencing and RNA-seq to identify enriched resistance mutations and pathway alterations.
The prevalence of KRAS G12C dual-state inhibitor target engagement in tumor biopsies from patients treated with these agents, compared to those treated with inactive-state inhibitors.
A cross-sectional analysis of tumor biopsies from 100 patients with KRAS G12C-mutant NSCLC treated with either a dual-state or inactive-state inhibitor, measuring KRAS G12C covalent adduct levels via mass spectrometry and pERK suppression via IHC at a single time point during treatment.